Oral leukoplakia and risk of progression to oral cancer: A population-based cohort study

Anil K. Chaturvedi, Natalia Udaltsova, Eric A. Engels, Jed A. Katzel, Elizabeth L. Yanik, Hormuzd A. Katki, Mark W. Lingen, Michael J. Silverberg

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Abstract

Background: The optimal clinical management of oral precancer remains uncertain. We investigated the natural history of oral leukoplakia, the most common oral precancerous lesion, to estimate the relative and absolute risks of progression to cancer, the predictive accuracy of a clinician's decision to biopsy a leukoplakia vis-a-visprogression, and histopathologic predictors of progression. Methods: We conducted a retrospective cohort study (1996-2012) of patients with oral leukoplakia (n = 4886), identified using electronic medical records within Kaiser Permanente Northern California. Among patients with leukoplakia who received a biopsy (n = 1888), we conducted a case-cohort study to investigate histopathologic predictors of progression. Analyses included indirect standardization and unweighted or weighted Cox regression. Results: Compared with the overall Kaiser Permanente Northern California population, oral cancer incidence was substantially elevated in oral leukoplakia patients (standardized incidence ratio = 40.8, 95% confidence interval [CI] = 34.8 to 47.6; n = 161 cancers over 22 582 person-years). Biopsied leukoplakias had a higher oral cancer risk compared with those that were not biopsied (adjusted hazard ratio = 2.38, 95% CI = 1.73 to 3.28). However, to identify a prevalent or incident oral cancer, the biopsy decision had low sensitivity (59.6%), low specificity (62.1%), and moderate positive-predictive value (5.1%). Risk of progression to oral cancer statistically significantly increased with the grade of dysplasia; 5-year competing risk-adjusted absolute risks were: leukoplakia overall = 3.3%, 95% CI = 2.7% to 3.9%; no dysplasia = 2.2%, 95% CI = 1.5% to 3.1%; mild-dysplasia = 11.9%, 95% CI = 7.1% to 18.1%; moderate-dysplasia = 8.7%, 95% CI = 3.2% to 17.9%; and severe dysplasia = 32.2%, 95% CI = 8.1%-60.0%. Yet 39.6% of cancers arose from biopsied leukoplakias without dysplasia. Conclusions: The modest accuracy of the decision to biopsy a leukoplakia vis-a-vispresence or eventual development of oral cancer highlights the need for routine biopsy of all leukoplakias regardless of visual or clinical impression. Leukoplakia patients, particularly those with dysplasia, need to be closely monitored for signs of early cancer.

Original languageEnglish
Pages (from-to)1047-1054
Number of pages8
JournalJournal of the National Cancer Institute
Volume112
Issue number10
DOIs
StatePublished - Oct 1 2020

Fingerprint

Dive into the research topics of 'Oral leukoplakia and risk of progression to oral cancer: A population-based cohort study'. Together they form a unique fingerprint.

Cite this